NEW YORK – Seqster PDM said Thursday that it is partnering with biopharmaceutical services firm United BioSource (UBC) to support patient engagement in decentralized clinical trials.
Financial terms of the agreement were not disclosed.
UBC, of Blue Bell, Pennsylvania, will integrate Seqster's data aggregation technology to gather clinical and observational research data and provide a portal for trial participants. San Diego-based Seqster collects individuals' health data from wearables, consumer genetic tests, electronic health records, and social determinants of health to create regularly updated longitudinal health records.
"Seqster's platform allows us to fundamentally modernize study designs by capitalizing on patient-mediated medical record release, thus enabling the acquisition of consolidated longitudinal healthcare records without the reliance on manual site-based data entry. This capability significantly enhances UBC’s ability to aggregate and deliver high-quality data for evidence generation," Aaron Berger, UBC's executive director for real-world evidence, said in a statement.
"This partnership enables participants, researchers, and pharma the flexibility to conduct clinical trials and observational studies beyond the traditional site-based setting to a fully decentralized or hybrid design while adding a critical patient engagement layer to every study," Seqster CEO Ardy Arianpour said. "In addition, the Seqster platform will facilitate patient recruitment, which is the number one reason most clinical trials fail."
This news follows last month's announcement that Seqster would work with the National Pancreas Foundation to create a registry of patients with pancreatic disease.